To elucidate the underlying metabolic mechanism responsible for GLUT3-induced tumour growth in vivo, we used a gas chromatography-time-of-flight mass spectrometry (GC-TOFMS)-based untargeted metabolomics approach to detect the impact of GLUT3-mediated glucose utilization on the global metabolism of CRC xenografts. The gene discussed is SLC2A3; the disease is neoplasm.